ONC · BeOne Medicines Ltd.
$372.58
-3.22 (-0.86%)
At close · Aug 27
Market Cap
$42.39B
Shares
113.12M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$375.80
Open$376.27
Day$372.01–377.66
52W close$260.27–377.47
Avg vol 30d403K
Short int1.3M · 1.1% float · 2.8d
Short vol65%
Last earningsAug 26, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Dec 6, 2026
Est · unconfirmed
· in 14 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+17%
above
RSI (14)
70
neutral
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
+28%
trailing
YTD return
+24%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $321 › 200d $318 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +46 funds added
Insider flow
Distributing
Net -$7.7M over 90 days · 100% sells
Short interest
Rising
1.13% of float · ▲ +44.9% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
282 holders — near 3-yr high, broad support
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
+22179%
Y/Y
Gross margin
1961%
contracting
EPS growth
+140%
Y/Y
Free cash flow
$941.7M
Valuation
P/E 851.8
rich
Balance sheet
$3.5B
net cash
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
2.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Total revenue
· Full Year 2026
Initiated
$6.3B – $6.5B
prior FY $5.34B
midpoint +19.8% Y/Y
GAAP operating expenses (combined R&D and SG&A)
· Full Year 2026
Initiated
$4.7B – $4.9B
Non-GAAP operating income
· Full Year 2026
Initiated
$1.45B – $1.55B
GAAP operating income
· Full Year 2026
Initiated
$750M – $850M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Total Revenue
· Full Year 2025
$5.1B – $5.3B
GAAP Operating Expenses (R&D and SG&A)
· Full Year 2025
$4.1B – $4.3B
Guided vs delivered
· last 1 settled
Total Revenue
Full Year 2025
guided $5.1B – $5.3B
$5.34B
Beat +2.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
70
Neutral
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Golden cross
50d $321 › 200d $318 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +46 funds added
Insider flow
Distributing
Net -$7.7M over 90 days · 100% sells
Short interest
Rising
1.13% of float · ▲ +44.9% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
282 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $260
Now $376 · 99%
Range high $377
vs 200-day avg +18%
vs 50-day avg +17%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Amgen in-licensed products global sales | 157M | the second quarter of 2026 | — |
| BRUKINSA global sales | 1.2B | the second quarter | — |
| BRUKINSA U.S. sales | 893M | the second quarter of 2026 | — |
| Free Cash Flow non-GAAP | 435.34M | the second quarter | — |
| Free Cash Flow (Non-GAAP) non-GAAP | $595.89M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Gross Margin as a percentage of global product sales (GAAP) | 90% | the second quarter of 2026 | — |
|
|
|||
| SG&A expenses as a percentage of product sales | 35% | the second quarter of 2026 | — |
| TEVIMBRA global sales | 229M | the second quarter of 2026 | — |
| Adjusted earnings per ADS - basic non-GAAP | $3.38 | Three Months Ended March 31, 2026 | — |
|
|
|||
| Adjusted earnings per ADS - diluted non-GAAP | $3.24 | Three Months Ended March 31, 2026 | — |
| Adjusted earnings per share - basic non-GAAP | $0.26 | Three Months Ended March 31, 2026 | — |
| Adjusted earnings per share - diluted non-GAAP | $0.25 | Three Months Ended March 31, 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $375.04M | Q1 2026 | — |
| SG&A as a percentage of product sales | 37% | Q1 2026 | — |
| Gross Margin ratio - China | 66.6% | the year ended December 31, 2025 | — |
| Gross Margin ratio - Ex-China | 97% | the year ended December 31, 2025 | — |
| Production or purchase quantity | 6,268,800 | the year ended December 31, 2025 | — |
| Sales quantity | 5,996,100 | the year ended December 31, 2025 | — |
| Stock quantity | 2,912,600 | as of December 31, 2025 | — |
| Adjusted earnings (loss) per ADS - diluted non-GAAP | $8.09 | Full Year 2025 | — |
| Adjusted earnings (loss) per share - basic non-GAAP | $0.65 | Full Year 2025 | — |
| Adjusted income from operations non-GAAP | $1.1B | Full Year 2025 | — |
GAAP → non-GAAP reconciliationGAAP GAAP income (loss) from operations 447.14M
+510.25M Share-based compensation expenses
+131.62M Depreciation
+10.07M Amortization of intangibles
+893K Other
= Adjusted income from operations 1.1B
|
|||
| Adjusted net income (loss) non-GAAP | $917.6M | Full Year 2025 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net income (loss) 286.93M
+510.25M Share-based compensation expenses
+131.62M Depreciation
+10.07M Amortization of intangibles
+893K Other
+75.63M Impairment of equity investments
+24.78M Discrete tax items
-122.56M Income tax effect of non-GAAP adjustments
= Adjusted net income (loss) 917.6M
|
|||
| Adjusted operating expenses non-GAAP | $3.6B | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ONC
this stock
BeOne Medicines Ltd.
|
$42.39B | +23.7% | +22179.2% | 851.8 | 1.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ONC | -0.3% | +14.9% | +28.3% | +18.9% | +23.7% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +0.1% | +9.8% | +15.9% | +16.4% | +11.4% |
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
229 filings
229 filers
Visit website
Investor relations